Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $315,566 - $366,824
21,094 New
21,094 $338,000
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $489,959 - $650,657
28,094 New
28,094 $584,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Frontier Asset Management, LLC Portfolio

Follow Frontier Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frontier Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frontier Asset Management, LLC with notifications on news.